ArticleBMC pulmonary medicine2026
Clinical characteristics and risk factors for mortality in pulmonary mucormycosis among patients with non-hematologic malignancies.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omics reveals regulatory networks and critical early-warning factors for severe disease progression in diabetic patients infected with SARS-CoV-2.Frontiers in immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary mucormycosis (PM) is a life-threatening fungal infection typically reported in neutropenic patients with hematologic malignancies (HM), but its features in non-hematologic malignancy (NHM) patients remain unclear. This study aimed to characterize the clinical presentation, treatment, and outcomes of PM in NHM patients.
methodsThis retrospective study (March 1, 2017-July 31, 2024) at Beijing Chaoyang Hospital included 46 NHM-PM patients, predominantly diabetes mellitus (DM) and solid organ transplantation (SOT). The primary outcome was 90-day all-cause mortality. Survival was analyzed using Kaplan-Meier curves and Cox regression, with adjustment for age, sex, and diabetes mellitus. The proportional hazards assumption was verified (GLOBAL p = 0.515).
resultsAmong 46 PM patients with NHM, DM was present in 71.7%. The 90-day mortality rate was 37.0% (17/46). Non-survivors had higher rates of respiratory failure, intensive care unit (ICU) admission, and septic shock, along with lower hemoglobin and higher D-dimer and procalcitonin (all P < 0.05). Univariable Cox regression identified solid organ transplantation (HR = 6.97), the use of immunosuppressants (HR = 5.58), elevated D-dimers, and elevated procalcitonin as significant mortality predictors (all P < 0.01), whereas longer hospital stay and longer time to treatment initiation were protective (both P < 0.05). Multivariable Cox regression confirmed the use of immunosuppressants as an independent risk factor (adjusted HR = 7.51, 95% CI: 2.72-20.74, P < 0.001). Kaplan-Meier curves showed significantly worse survival for the use of immunosuppressants and SOT recipients (log-rank P < 0.001 for both).
conclusionsThe use of immunosuppressants and SOT are both important factors associated with 90-day mortality in NHM-PM patients. These findings highlight the poor prognosis associated with immunosuppression and support early, aggressive intervention in this high-risk population. Validation in larger cohorts is warranted.
Indexed as
Identifiers
42414943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.